| Gene symbol | GRB2 | Synonyms | ASH, EGFRBP-GRB2, Grb3-3, MST084, MSTP084, NCKAP2 | Type of gene | protein-coding |
| Chromosome | 17 | Map location | 17q25.1 | dbXrefs | |
| Gene perturbation-related omics dataset | PerturbAtlas | ||||
| Description | growth factor receptor bound protein 2 | ||||
| GTO ID | GTC1613 |
| Trial ID | NCT02781883 |
| Disease | Acute Myeloid Leukemia |
| Altered gene | GRB2 |
| Therapeutic/Target gene | Target gene |
| Therapy | ASO |
| Treatment | BP1001|Liposomal Grb2 Antisense Oligonucleotide|Liposomal Grb-2|L-Grb-2 |
| Co-treatment | Ventoclax|decitabine |
| Phase | Phase2 |
| Recruitment status | Recruiting |
| Title | A Phase IIa, Open-label, Clinical Trial to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of BP1001 (a Liposomal Grb2 Antisense Oligonucleotide) in Combination With Venetoclax Plus Decitabine in Patients With AML Who Are Ineligible for Intensive Induction Therapy |
| Year | 2016 |
| Country | United States |
| Company sponsor | Bio-Path Holdings, Inc. |
| Other ID(s) | BP1001-201-AML |
| Vector information | |||
|
|||
| Cohort1: BP1001_Ventoclax_decitabine_Untreated AML | |||||
|
|||||
| Cohort2: BP1001_Ventoclax_decitabine_Refractory/Relapsed AML | |||||
|
|||||
| Cohort3: BP1001_decitabine | |||||
|
|||||